Maggie Hassan

It is clear that patients need access to more medical providers who can recognize and treat long COVID.

I think that trying to design an entire government agency would take me a little longer than the two minutes I am looking at right here.

I really appreciate it, and it is really a follow-on to what you were just discussing with Senator Blumenthal.

I believe must experience a recusal process.

What obstacles has the Board encountered without subpoena authority and do you believe that the Board needs this authority to be effective?

What metrics should Congress use to measure the Board's success?

What do adequate, ethical guardrails look for both the members and topic selection processes to ensure that the Board's work is protected from undue influence or conflict of interest?

Thank you very much, and thank you, Mr. Chair.

I think that this is completely unacceptable and obviously it just pisses me off.

I also have been really encouraged by some of the preliminary results that we are seeing for around enrolling diabetic or pre-diabetic patients in food as medicine initiatives.

I hear from Minnesotans every single day who tell me that they are rationing this medicine that keeps them alive.

How can Congress ensure that all populations that can benefit from this medication have access to it?

I appreciate your work in this area.

Last year, three major insulin companies announced that they would limit the cost of insulin to $35 a month for all patients.

I hear from Minnesotans every single day who tell me that they are rationing this medicine that keeps them alive.

I think that this is completely unacceptable and obviously it just pisses me off.

I also have been really encouraged by some of the preliminary results that we are seeing for around enrolling diabetic or pre-diabetic patients in food as medicine initiatives.

How can Congress ensure that all populations that can benefit from this medication have access to it?

I appreciate your work in this area.

Cell therapies have provided a pathway to the cures.

Last year, three major insulin companies announced that they would limit the cost of insulin to $35 a month for all patients.

JDRF supports the bipartisan INSULIN Act of 2023, led by Senators Collins and Shaheen.

I think that this is completely unacceptable and obviously it just pisses me off.

I also have been really encouraged by some of the preliminary results that we are seeing for around enrolling diabetic or pre-diabetic patients in food as medicine initiatives.

I appreciate your work in this area.